{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:17:19Z","timestamp":1792649839320,"version":"4.5.0"},"reference-count":51,"publisher":"National Academy of Sciences","issue":"22","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":183,"URL":"https:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA080124"],"award-info":[{"award-number":["P01-CA080124"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA224173"],"award-info":[{"award-number":["U01CA224173"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-10-1-0016"],"award-info":[{"award-number":["W81XWH-10-1-0016"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009559","name":"Life Sciences Research Foundation","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100009559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0034"],"award-info":[{"award-number":["W81XWH-14-1-0034"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA073479"],"award-info":[{"award-number":["T32-CA073479"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2019,5,28]]},"abstract":"<jats:p>Cancer-associated fibroblasts (CAFs) can either suppress or support T lymphocyte activity, suggesting that CAFs may be reprogrammable to an immunosupportive state. Angiotensin receptor blockers (ARBs) convert myofibroblast CAFs to a quiescent state, but whether ARBs can reprogram CAFs to promote T lymphocyte activity and enhance immunotherapy is unknown. Moreover, ARB doses are limited by systemic adverse effects such as hypotension due to the importance of angiotensin signaling outside tumors. To enhance the efficacy and specificity of ARBs in cancer with the goal of revealing their effects on antitumor immunity, we developed ARB nanoconjugates that preferentially accumulate and act in tumors. We created a diverse library of hundreds of acid-degradable polymers and chemically linked ARBs to the polymer most sensitive to tumor pH. These tumor microenvironment-activated ARBs (TMA-ARBs) remain intact and inactive in circulation while achieving high concentrations in tumors, wherein they break down to active ARBs. This tumor-preferential activity enhances the CAF-reprogramming effects of ARBs while eliminating blood pressure-lowering effects. Notably, TMA-ARBs alleviate immunosuppression and improve T lymphocyte activity, enabling dramatically improved responses to immune-checkpoint blockers in mice with primary as well as metastatic breast cancer.<\/jats:p>","DOI":"10.1073\/pnas.1819889116","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T17:15:47Z","timestamp":1556644547000},"page":"10674-10680","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":196,"title":["Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy"],"prefix":"10.1073","volume":"116","author":[{"given":"Vikash P.","family":"Chauhan","sequence":"first","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"},{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ;"},{"name":"Harvard School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy X.","family":"Chen","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"},{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ;"},{"name":"Harvard School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tong","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ;"},{"name":"Laboratory for Biomaterials and Drug Delivery, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"},{"name":"Department of Anesthesiology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"},{"name":"Division of Critical Care Medicine, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Rosa","family":"Ng","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-8203","authenticated-orcid":false,"given":"John D.","family":"Martin","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"},{"name":"Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Naxerova","sequence":"additional","affiliation":[{"name":"Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle W.","family":"Wu","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peigen","family":"Huang","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Boucher","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Kohane","sequence":"additional","affiliation":[{"name":"Laboratory for Biomaterials and Drug Delivery, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"},{"name":"Department of Anesthesiology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"},{"name":"Division of Critical Care Medicine, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-0492","authenticated-orcid":false,"given":"Robert","family":"Langer","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ;"},{"name":"Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian SL","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen DS","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321\u2013330.","journal-title":"Nature"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa A","year":"2018","unstructured":"Costa A, . (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33:463\u2013479.e10.","journal-title":"Cancer Cell"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman M","year":"2010","unstructured":"Kraman M, . (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330:827\u2013830.","journal-title":"Science"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig C","year":"2013","unstructured":"Feig C, . (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110:20212\u201320217.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour S","year":"2015","unstructured":"Shalapour S, . (2015) Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521:94\u201398.","journal-title":"Nature"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen IX","year":"2019","unstructured":"Chen IX, . (2019) Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci USA 116:4558\u20134566.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon H","year":"2012","unstructured":"Salmon H, . (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122:899\u2013910.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ccr.2014.06.003","article-title":"Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure","volume":"26","author":"Chauhan VP","year":"2014","unstructured":"Chauhan VP, . (2014) Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26:14\u201315.","journal-title":"Cancer Cell"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan VP","year":"2013","unstructured":"Chauhan VP, . (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4:2516.","journal-title":"Nat Commun"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos T","year":"2012","unstructured":"Stylianopoulos T, . (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109:15101\u201315108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum IB","year":"2014","unstructured":"Barsoum IB, Smallwood CA, Siemens DR, Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74:665\u2013674.","journal-title":"Cancer Res"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto A","year":"2012","unstructured":"Calcinotto A, . (2012) Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 72:2746\u20132756.","journal-title":"Cancer Res"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman MZ","year":"2014","unstructured":"Noman MZ, . (2014) PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781\u2013790.","journal-title":"J Exp Med"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells","volume":"475","author":"Facciabene A","year":"2011","unstructured":"Facciabene A, . (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475:226\u2013230.","journal-title":"Nature"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir BC","year":"2014","unstructured":"\u00d6zdemir BC, . (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719\u2013734.","journal-title":"Cancer Cell"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman MH","year":"2014","unstructured":"Sherman MH, . (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80\u201393.","journal-title":"Cell"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia","volume":"26","author":"Jain RK","year":"2014","unstructured":"Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26:605\u2013622.","journal-title":"Cancer Cell"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong B","year":"2011","unstructured":"Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 108:2909\u20132914.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10637-013-9972-5","article-title":"A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2","volume":"31","author":"Nakai Y","year":"2013","unstructured":"Nakai Y, . (2013) A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 31:1294\u20131299.","journal-title":"Invest New Drugs"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2018.36.15_suppl.4116","article-title":"Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study","volume":"36","author":"Murphy JE","year":"2018","unstructured":"Murphy JE, . (2018) Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study. J Clin Oncol 36:4116.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/10837450.2016.1265553","article-title":"Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer","volume":"23","author":"Xia T","year":"2018","unstructured":"Xia T, . (2018) Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. Pharm Dev Technol 23:13\u201321.","journal-title":"Pharm Dev Technol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm0297-177","article-title":"Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation","volume":"3","author":"Helmlinger G","year":"1997","unstructured":"Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3:177\u2013182.","journal-title":"Nat Med"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0360-3016(85)90217-2","article-title":"pH distribution in human tumors","volume":"11","author":"Thistlethwaite AJ","year":"1985","unstructured":"Thistlethwaite AJ, Leeper DB, Moylan Iii DJ, Nerlinger RE (1985) pH distribution in human tumors. Int J Radiat Oncol Biol Phys 11:1647\u20131652.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0277-5379(85)90216-0","article-title":"Human tumour pH and its variation","volume":"21","author":"Wike-Hooley JL","year":"1985","unstructured":"Wike-Hooley JL, van den Berg AP, van der Zee J, Reinhold HS (1985) Human tumour pH and its variation. Eur J Cancer Clin Oncol 21:785\u2013791.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.7434025","article-title":"pH-sensitive liposomes: Possible clinical implications","volume":"210","author":"Yatvin MB","year":"1980","unstructured":"Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M (1980) pH-sensitive liposomes: Possible clinical implications. Science 210:1253\u20131255.","journal-title":"Science"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1039\/c2ib20135f","article-title":"Stimulus-responsive nanopreparations for tumor targeting","volume":"5","author":"Zhu L","year":"2013","unstructured":"Zhu L, Torchilin VP (2013) Stimulus-responsive nanopreparations for tumor targeting. Integr Biol 5:96\u2013107.","journal-title":"Integr Biol"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13905","article-title":"MicroRNA silencing for cancer therapy targeted to the tumour microenvironment","volume":"518","author":"Cheng CJ","year":"2015","unstructured":"Cheng CJ, . (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518:107\u2013110.","journal-title":"Nature"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1021\/ja026925r","article-title":"A novel strategy for encapsulation and release of proteins: Hydrogels and microgels with acid-labile acetal cross-linkers","volume":"124","author":"Murthy N","year":"2002","unstructured":"Murthy N, Thng YX, Schuck S, Xu MC, Fr\u00e9chet JMJ (2002) A novel strategy for encapsulation and release of proteins: Hydrogels and microgels with acid-labile acetal cross-linkers. J Am Chem Soc 124:12398\u201312399.","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/bc050176w","article-title":"Polyketal nanoparticles: A new pH-sensitive biodegradable drug delivery vehicle","volume":"16","author":"Heffernan MJ","year":"2005","unstructured":"Heffernan MJ, Murthy N (2005) Polyketal nanoparticles: A new pH-sensitive biodegradable drug delivery vehicle. Bioconjug Chem 16:1340\u20131342.","journal-title":"Bioconjug Chem"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1021\/bc700442g","article-title":"Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases","volume":"19","author":"Yang SC","year":"2008","unstructured":"Yang SC, Bhide M, Crispe IN, Pierce RH, Murthy N (2008) Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem 19:1164\u20131169.","journal-title":"Bioconjug Chem"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1021\/ja016288p","article-title":"Accelerated discovery of synthetic transfection vectors: Parallel synthesis and screening of a degradable polymer library","volume":"123","author":"Lynn DM","year":"2001","unstructured":"Lynn DM, Anderson DG, Putnam D, Langer R (2001) Accelerated discovery of synthetic transfection vectors: Parallel synthesis and screening of a degradable polymer library. J Am Chem Soc 123:8155\u20138156.","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/anie.200351244","article-title":"Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery","volume":"42","author":"Anderson DG","year":"2003","unstructured":"Anderson DG, Lynn DM, Langer R (2003) Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl 42:3153\u20133158.","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral H","year":"2011","unstructured":"Cabral H, . (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6:815\u2013823.","journal-title":"Nat Nanotechnol"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan VP","year":"2012","unstructured":"Chauhan VP, . (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383\u2013388.","journal-title":"Nat Nanotechnol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1021\/jacs.6b11181","article-title":"Substituent effects on the pH sensitivity of acetals and ketals and their correlation with encapsulation stability in polymeric nanogels","volume":"139","author":"Liu B","year":"2017","unstructured":"Liu B, Thayumanavan S (2017) Substituent effects on the pH sensitivity of acetals and ketals and their correlation with encapsulation stability in polymeric nanogels. J Am Chem Soc 139:2306\u20132317.","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio J","year":"2016","unstructured":"Incio J, . (2016) Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov 6:852\u2013869.","journal-title":"Cancer Discov"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo V","year":"2013","unstructured":"Cortez-Retamozo V, . (2013) Angiotensin II drives the production of tumor-promoting macrophages. Immunity 38:296\u2013308.","journal-title":"Immunity"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter M","year":"2017","unstructured":"Pinter M, Jain RK (2017) Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 9:eaan5616.","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-17-0256","article-title":"Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma","volume":"23","author":"Liu H","year":"2017","unstructured":"Liu H, . (2017) Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma. Clin Cancer Res 23:5959\u20135969.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz GT","year":"2014","unstructured":"Motz GT, . (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607\u2013615.","journal-title":"Nat Med"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"14776","DOI":"10.1073\/pnas.1416498111","article-title":"Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts","volume":"111","author":"Ammirante M","year":"2014","unstructured":"Ammirante M, Shalapour S, Kang Y, Jamieson CAM, Karin M (2014) Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA 111:14776\u201314781.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/ni730","article-title":"Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells","volume":"2","author":"Tzachanis D","year":"2001","unstructured":"Tzachanis D, . (2001) Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2:1174\u20131182.","journal-title":"Nat Immunol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang Y","year":"2012","unstructured":"Huang Y, . (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109:17561\u201317566.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh PC","year":"2014","unstructured":"Tumeh PC, . (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571.","journal-title":"Nature"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei SC","year":"2017","unstructured":"Wei SC, . (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170:1120\u20131133.e17.","journal-title":"Cell"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade J","year":"2010","unstructured":"Fourcade J, . (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175\u20132186.","journal-title":"J Exp Med"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros C","year":"2016","unstructured":"Boutros C, . (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473\u2013486.","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan S","year":"2018","unstructured":"Mariathasan S, . (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548.","journal-title":"Nature"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello DVF","year":"2018","unstructured":"Tauriello DVF, . (2018) TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554:538\u2013543.","journal-title":"Nature"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"0004","DOI":"10.1038\/s41551-016-0004","article-title":"Solid stress and elastic energy as measures of tumour mechanopathology","volume":"1","author":"Nia HT","year":"2016","unstructured":"Nia HT, . (2016) Solid stress and elastic energy as measures of tumour mechanopathology. Nat Biomed Eng 1:0004.","journal-title":"Nat Biomed Eng"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1819889116","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1819889116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T02:08:56Z","timestamp":1694830136000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1819889116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":51,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,5,28]]}},"alternative-id":["10.1073\/pnas.1819889116"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1819889116","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"2019-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}